X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-for-the-treatment-of-idh1-mutated-relapsed-or-refractory-rr-myelodysplastic-syndromes-mds-301966382.html
https://www.prnewswire.com/news-releases/fda-approves-new-therapy-for-rare-form-of-blood-cancers-called-myelodysplastic-syndromes-301966415.html
https://www.prnewswire.com/news-releases/servier-announces-fda-filing-acceptance-and-priority-review-for-tibsovo-ivosidenib-tablets-in-the-treatment-of-idh1-mutated-relapsed-or-refractory-rr-myelodysplastic-syndromes-mds-301901315.html
https://www.prnewswire.com/news-releases/servier-presents-updated-results-for-tibsovo-ivosidenib-tablets-in-idh1-mutated-relapsedrefractory-myelodysplastic-syndromes-at-the-2023-european-hematology-association-eha-congress-301846844.html
https://www.ema.europa.eu/en/documents/overview/tibsovo-epar-medicine-overview_en.pdf
https://www.pharmaceutical-technology.com/news/servier-tibsovo-ec-cancer/
https://www.prnewswire.com/news-releases/servier-receives-a-positive-chmp-opinion-for-tibsovo-in-idh1-mutated-acute-myeloid-leukemia-aml-and-cholangiocarcinoma-cca-patients-301755348.html
https://www.prnewswire.com/news-releases/servier-presents-patient-follow-up-data-from-the-phase-3-agile-study-at-ash-2022-301699785.html
https://www.biopharmadive.com/news/rigel-pharmaceuticals-leukemia-rezlidhia-fda-approval/637843/
https://endpts.com/in-final-pivot-from-cancer-to-rare-disease-agios-offloads-its-share-of-tibsovo-royalties-for-131m/
https://www.prnewswire.com/news-releases/servier-leverages-mission-bios-tapestri-platform-to-uncover-aml-resistance-mechanisms-in-pivotal-tibsovo-ivosidenib-clinical-trial-301625098.html
https://apnews.com/article/health-cancer-clinical-trials-8a62525c9b47e96447f4f108dfd42791
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tibsovo-ivosidenib-40790.pdf
https://www.fiercebiotech.com/biotech/servier-takes-aim-us-oncology-market-doubles-rd-labspace-boston
https://endpts.com/servier-expands-tibsovo-label-with-first-combination-ok-in-a-rare-form-of-aml/
https://www.asiaone.com/business/servier-announces-fda-approval-tibsovo-ivosidenib-tablets-combination-azacitidine-patients
https://www.prnewswire.com/news-releases/phase-3-agile-data-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-published-in-the-new-england-journal-of-medicine-301529694.html
https://www.prnewswire.com/news-releases/servier-submits-a-marketing-authorization-application-to-the-european-medicines-agency-ema-for-tibsovo-ivosidenib-tablets-for-patients-with-idh1-mutated-acute-myeloid-leukemia-aml-and-cholangiocarcinoma-301500159.html
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b-vs-control-arm-in-the-number-of-patients-potentially-evaluable-for-the-primary-endpoint-of-the-pivotal-phase-3-sierra-trial-at-the-63rd-as-301442794.html
https://finance.yahoo.com/news/data-ash-2021-reinforces-strength-000500101.html
https://www.biospace.com/article/releases/servier-announces-fda-filing-acceptance-and-priority-review-for-tibsovo-ivosidenib-tablets-in-idh1-mutated-cholangiocarcinoma/
https://www.thepharmaletter.com/article/new-phase-iii-data-falls-short-on-os-but-supports-snda-filing-for-agios-tibsovo-in-1st-qtr-2021
https://www.globenewswire.com/news-release/2020/09/21/2096376/0/en/Agios-Announces-Final-Overall-Survival-Data-from-Phase-3-ClarIDHy-Study-of-TIBSOVO-ivosidenib-tablets-in-Previously-Treated-IDH1-Mutant-Cholangiocarcinoma-Patients.html#:~:text=TIBSOVO%C2%AE%20is%20not%20approved,treated%20advanced%20IDH1%2Dmutant%20cholangiocarcinoma.&text=Cholangiocarcinoma%20is%20a%20rare%20cancer,and%20outside%20of%20the%20liver.
https://www.targetedonc.com/view/ivosidenib-improves-overall-survival-in-advanced-idh1-cholangiocarcinoma
https://www.fiercepharma.com/marketing/agios-despite-fda-nod-calls-it-quit-tibsovo-european-aml-app-after-ema-snub
https://endpts.com/european-regulators-spurn-agios-aml-drug-tibsovo-unconvinced-by-the-same-thin-phi-data-that-won-over-the-fda/
https://www.globenewswire.com/news-release/2020/09/21/2096376/0/en/Agios-Announces-Final-Overall-Survival-Data-from-Phase-3-ClarIDHy-Study-of-TIBSOVO-ivosidenib-tablets-in-Previously-Treated-IDH1-Mutant-Cholangiocarcinoma-Patients.html
https://www.globenewswire.com/news-release/2020/05/19/2035513/0/en/Agios-Announces-Publication-of-TIBSOVO-Phase-3-Data-in-The-Lancet-Oncology-Demonstrating-Significant-Improvement-in-Progression-Free-Survival-Compared-to-Placebo-in-Previously-Trea.html
https://www.heatbio.com/news-media/news-releases/detail/657/positive-survival-data-from-phase-2-lung-cancer-trial
https://endpts.com/agios-lines-up-solid-phiii-data-to-back-tibsovos-use-in-bile-duct-cancer-ahead-of-planned-snda/
https://www.biospectrumasia.com/news/25/13601/cstone-submits-new-drug-application-for-tibsovor-for-treatment-of-relapsed-refractory-aml.html
https://www.prnewswire.com/news-releases/cstone-partner-agios-announces-the-phase-3-claridhy-trial-of-tibsovo-ivosidenib-achieved-its-primary-endpoint-300855789.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation
https://www.fiercebiotech.com/biotech/agios-blood-cancer-drug-lead-jumps-ship-to-aprea-therapeutics
https://www.news-medical.net/news/20180730/Ivosidenib-receives-FDA-approval-to-treat-acute-myeloid-leukemia-patients-with-IDH1-mutation.aspx
http://www.pharmatimes.com/news/us_approves_first-in-class_targeted_aml_therapy_1245302
https://www.biospectrumasia.com/news/34/11353/agios-receives-nod-for-ivosidenib-.html
https://endpts.com/agios-scores-its-second-new-drug-approval-ivosidenib-heads-to-the-aml-market/
Market Place
Share 
